James A. Kashanian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James A. Kashanian has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Hriday P. Bhambhvani
Department of Urology, NewYork-Presbyterian Hospital, New York, New York
5 shared publicationsNahid Punjani
Department of Urology, Weill Cornell Medicine, New York, USA
5 shared publicationsArt Sedrakyan
Department of Surgery, Weill Cornell Medicine, New York, USA
4 shared publicationsCaroline Kang
Weill Medical College of Cornell University
4 shared publicationsGal Wald
Department of Urology, New York-Presbyterian Hospital, New York, NY; Department of Urology, Weill Cornell Medical Center, New York, NY
4 shared publicationsRon Golan
Department of Urology, Weill Cornell Medicine, New York, New York
4 shared publications
Latest Publications
- 1 July 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (4) , 422-430
Sperm Retrieval in Men With AZFc Microdeletions Is Independent of Age but Associated With Intermediate Follicle-Stimulating Hormone Levels
Y-chromosome microdeletions, particularly in the AZFc region, are a common genetic cause of male infertility. This study evaluates sperm retrieval rates (SRR) and testicular histology across age groups in men with isolated AZFc deletions. We identified men with isolated complete AZFc microdeletions who underwent mTESE from 2000-2024. Genitourinary pathology reports categorized histology as Sertoli-cell only, tubular atrophy, maturation arrest, or hypospermatogenesis. Chi-square tests compared histology and SRR. Multivariable logistic regression assessed factors associated with successful sperm retrieval. Of 1,473 patients who underwent Y-chromosome microdeletion testing, 72 with isolated AZFc microdeletions underwent mTESE. Patients were stratified by age ≤35 years (n=51) and >35 years (n=21). Overall, germ cells were identified in 59.7% of cases, with no difference between patients ≤35 years (58.8%) and >35 years (61.9%) (P=0.81). The overall SRR was 50%, with no difference by age group (≤35 years: 51.0%, >35 years: 47.6%; P=0.80). On multivariable analysis, age >35 years (OR 0.82, 95% CI [0.28, 2.40]) and the presence of spermatogenesis during biopsy (OR 1.66, 95% CI [0.59, 4.69]) were not associated with SRR. FSH levels between 12.4-24.0 mIU/mL were associated with higher SRR (OR 7.04, 95% CI [1.83, 27.1]). Patient age was not a strong predictor of sperm retrieval success in men with complete AZFc deletion. FSH levels within an intermediate range were associated with higher sperm retrieval rates, suggesting hormonal context may inform patient counseling. Reproductive urologists should counsel patients that age alone is unlikely to meaningfully influence sperm retrieval.
- 1 July 2026
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 13 (4) , 422-430
Sperm Retrieval in Men With AZFc Microdeletions Is Independent of Age but Associated With Intermediate Follicle-Stimulating Hormone Levels
Y-chromosome microdeletions, particularly in the AZFc region, are a common genetic cause of male infertility. This study evaluates sperm retrieval rates (SRR) and testicular histology across age groups in men with isolated AZFc deletions. We identified men with isolated complete AZFc microdeletions who underwent mTESE from 2000-2024. Genitourinary pathology reports categorized histology as Sertoli-cell only, tubular atrophy, maturation arrest, or hypospermatogenesis. Chi-square tests compared histology and SRR. Multivariable logistic regression assessed factors associated with successful sperm retrieval. Of 1,473 patients who underwent Y-chromosome microdeletion testing, 72 with isolated AZFc microdeletions underwent mTESE. Patients were stratified by age ≤35 years (n=51) and >35 years (n=21). Overall, germ cells were identified in 59.7% of cases, with no difference between patients ≤35 years (58.8%) and >35 years (61.9%) (P=0.81). The overall SRR was 50%, with no difference by age group (≤35 years: 51.0%, >35 years: 47.6%; P=0.80). On multivariable analysis, age >35 years (OR 0.82, 95% CI [0.28, 2.40]) and the presence of spermatogenesis during biopsy (OR 1.66, 95% CI [0.59, 4.69]) were not associated with SRR. FSH levels between 12.4-24.0 mIU/mL were associated with higher SRR (OR 7.04, 95% CI [1.83, 27.1]). Patient age was not a strong predictor of sperm retrieval success in men with complete AZFc deletion. FSH levels within an intermediate range were associated with higher sperm retrieval rates, suggesting hormonal context may inform patient counseling. Reproductive urologists should counsel patients that age alone is unlikely to meaningfully influence sperm retrieval.
- 21 August 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (12) , 1015-1016
Response to Comment on: Comparative outcomes of intralesional collagenase injection for Peyronie’s disease: acute vs. stable phase treatment
- 21 August 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (12) , 1015-1016
Response to Comment on: Comparative outcomes of intralesional collagenase injection for Peyronie’s disease: acute vs. stable phase treatment
- 1 April 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (12) , 965-969
Comparative outcomes of intralesional collagenase injection for Peyronie’s disease: acute vs. stable phase treatment
Collagenase clostridium histolyticum (CCH) was FDA-approved for treating Peyronie’s Disease (PD), demonstrating significant curvature improvement in patients during the stable phase of disease. In this retrospective cohort study, we aimed to assess the safety and effectiveness of intralesional CCH injections during the acute phase of PD. We retrospectively evaluated all men who received intralesional CCH for PD at a single academic institution between July 2017 and January 2023, focusing on patient demographics, comorbidities, pre- and post-treatment curvature, and adverse events. Patients in the acute phase had symptoms for ≤ 12 months with penile pain and/or curvature changes. A total of 100 patients treated with intralesional CCH injections for PD were included. Percent change in penile curvature was not significantly different between acute and stable phases (37.02 vs. 34.01%, p = 0.57). A total of 55 patients (76.39%) in the stable phase and 23 patients (82.14%) in the acute phase showed improvement in curvature, with no significant differences in curvature outcomes or adverse events between the two groups. This study contributes to the growing evidence that intralesional CCH treatment during the acute phase of PD is safe and effective.
- 1 April 2025
- Published by Springer Nature in International Journal Of Impotence Research
- Vol. 37 (12) , 965-969
Comparative outcomes of intralesional collagenase injection for Peyronie’s disease: acute vs. stable phase treatment
Collagenase clostridium histolyticum (CCH) was FDA-approved for treating Peyronie’s Disease (PD), demonstrating significant curvature improvement in patients during the stable phase of disease. In this retrospective cohort study, we aimed to assess the safety and effectiveness of intralesional CCH injections during the acute phase of PD. We retrospectively evaluated all men who received intralesional CCH for PD at a single academic institution between July 2017 and January 2023, focusing on patient demographics, comorbidities, pre- and post-treatment curvature, and adverse events. Patients in the acute phase had symptoms for ≤ 12 months with penile pain and/or curvature changes. A total of 100 patients treated with intralesional CCH injections for PD were included. Percent change in penile curvature was not significantly different between acute and stable phases (37.02 vs. 34.01%, p = 0.57). A total of 55 patients (76.39%) in the stable phase and 23 patients (82.14%) in the acute phase showed improvement in curvature, with no significant differences in curvature outcomes or adverse events between the two groups. This study contributes to the growing evidence that intralesional CCH treatment during the acute phase of PD is safe and effective.
- 20 November 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (8) , 2787-2794
Erectile dysfunction is an underdiagnosed consequence of low anterior resection and abdominoperineal resection for colorectal cancer
To explore the frequency and predictive factors of erectile dysfunction diagnosis after colorectal cancer surgery. The Surveillance, Epidemiology, and End Results—Medicare database was used to identify a national sample of men undergoing surgery for colorectal cancer from 2004 to 2015. Men aged > 65 years with any index surgery within 1 year of diagnosis of colorectal cancer were included. Men with a history of prior erectile dysfunction, metastatic cancer, or genitourinary cancer prior to their index procedure were excluded. The primary outcome was a new diagnosis of erectile dysfunction within 2 years of the index procedure. A total of 28,248 men aged > 65 years who underwent colorectal cancer surgery were identified. The rates of erectile dysfunction diagnosis 2 years after surgery were 3.6% for hemicolectomy, 5.3% for low anterior resection, and 6.4% for abdominoperineal resection. On multivariable analysis, low anterior resection (HR: 1.27, 95%CI 1.08 to 1.51, p < 0.01) and abdominoperineal resection (HR: 1.49, 95%CI 1.14 − 1.93, p < 0.01) were independently associated with increased risk of erectile dysfunction compared to hemicolectomy. Minimally invasive surgery was independently associated with an increased risk of erectile dysfunction compared to open surgery (HR: 1.44, 95% CI 1.25–1.65, p < 0.001). Compared to hemicolectomy, men treated with low anterior resection and abdominoperineal resection have a higher risk of being diagnosed with erectile dysfunction within 2 years of treatment. The absolute rate of erectile dysfunction diagnosis was low compared to rates reported in prior controlled trials, suggesting that patients are underdiagnosed in real-world settings.
- 20 November 2024
- Published by Springer Nature in Updates in Surgery
- Vol. 76 (8) , 2787-2794
Erectile dysfunction is an underdiagnosed consequence of low anterior resection and abdominoperineal resection for colorectal cancer
To explore the frequency and predictive factors of erectile dysfunction diagnosis after colorectal cancer surgery. The Surveillance, Epidemiology, and End Results—Medicare database was used to identify a national sample of men undergoing surgery for colorectal cancer from 2004 to 2015. Men aged > 65 years with any index surgery within 1 year of diagnosis of colorectal cancer were included. Men with a history of prior erectile dysfunction, metastatic cancer, or genitourinary cancer prior to their index procedure were excluded. The primary outcome was a new diagnosis of erectile dysfunction within 2 years of the index procedure. A total of 28,248 men aged > 65 years who underwent colorectal cancer surgery were identified. The rates of erectile dysfunction diagnosis 2 years after surgery were 3.6% for hemicolectomy, 5.3% for low anterior resection, and 6.4% for abdominoperineal resection. On multivariable analysis, low anterior resection (HR: 1.27, 95%CI 1.08 to 1.51, p < 0.01) and abdominoperineal resection (HR: 1.49, 95%CI 1.14 − 1.93, p < 0.01) were independently associated with increased risk of erectile dysfunction compared to hemicolectomy. Minimally invasive surgery was independently associated with an increased risk of erectile dysfunction compared to open surgery (HR: 1.44, 95% CI 1.25–1.65, p < 0.001). Compared to hemicolectomy, men treated with low anterior resection and abdominoperineal resection have a higher risk of being diagnosed with erectile dysfunction within 2 years of treatment. The absolute rate of erectile dysfunction diagnosis was low compared to rates reported in prior controlled trials, suggesting that patients are underdiagnosed in real-world settings.
Real‐world practice in Peyronie's disease management: Results from a national survey of urologists
BackgroundDespite many available treatments for Peyronie's disease (PD), practice patterns of available therapeutics are not well characterized. ObjectiveWe conducted a national survey of urologists to characterize real-world practice patterns of PD management and to characterize the use of therapies discouraged by the American Urological Association guidelines on PD management. Materials and methodsA 34-item survey was distributed via RedCap to urologists who treat patients with PD in all American Urological Association sections. Questions elicited demographic information as well as practices in the diagnosis and treatment of PD. Comparisons were made with Pearson's chi-squared test. The primary outcome was reported use of therapies discouraged by the American Urological Association guidelines on PD. ResultsA total of 145 respondents completed the survey, of whom 19% were fellowship trained in andrology/sexual medicine, 36% practiced in an academic setting, and 50% had at least 20 years in practice. Only 60% of respondents reporting performing in-office curvature assessment prior to commencing intralesional injection or surgical treatment, with higher prevalence in andrology/sexual medicine fellowship-trained versus non-fellowship-trained urologists (85% vs. 54%, p = 0.003). The most popular treatment modalities were collagenase clostridium histolyticum (61% of respondents), phosphodiesterase-5 inhibitors (54%), and penile traction (53%). Twenty-one percent of respondents reported currently using a treatment that is explicitly discouraged by the American Urological Association guidelines (extracorporeal shockwave therapy for curvature, L-carnitine, omega-3 fatty acids, or vitamin E). DiscussionPatients seeking PD treatment may be offered different therapies, some of which are not evidence-based, depending on the treating urologist. This study is limited by self-selection and response bias. Its strength is that it represents a cross-sectional overview of real-world practice patterns in PD management, which has not been previously described. ConclusionsA significant proportion of urologists reported PD management practices that are not evidence-based and not guideline-supported.
Real‐world practice in Peyronie's disease management: Results from a national survey of urologists
BackgroundDespite many available treatments for Peyronie's disease (PD), practice patterns of available therapeutics are not well characterized. ObjectiveWe conducted a national survey of urologists to characterize real-world practice patterns of PD management and to characterize the use of therapies discouraged by the American Urological Association guidelines on PD management. Materials and methodsA 34-item survey was distributed via RedCap to urologists who treat patients with PD in all American Urological Association sections. Questions elicited demographic information as well as practices in the diagnosis and treatment of PD. Comparisons were made with Pearson's chi-squared test. The primary outcome was reported use of therapies discouraged by the American Urological Association guidelines on PD. ResultsA total of 145 respondents completed the survey, of whom 19% were fellowship trained in andrology/sexual medicine, 36% practiced in an academic setting, and 50% had at least 20 years in practice. Only 60% of respondents reporting performing in-office curvature assessment prior to commencing intralesional injection or surgical treatment, with higher prevalence in andrology/sexual medicine fellowship-trained versus non-fellowship-trained urologists (85% vs. 54%, p = 0.003). The most popular treatment modalities were collagenase clostridium histolyticum (61% of respondents), phosphodiesterase-5 inhibitors (54%), and penile traction (53%). Twenty-one percent of respondents reported currently using a treatment that is explicitly discouraged by the American Urological Association guidelines (extracorporeal shockwave therapy for curvature, L-carnitine, omega-3 fatty acids, or vitamin E). DiscussionPatients seeking PD treatment may be offered different therapies, some of which are not evidence-based, depending on the treating urologist. This study is limited by self-selection and response bias. Its strength is that it represents a cross-sectional overview of real-world practice patterns in PD management, which has not been previously described. ConclusionsA significant proportion of urologists reported PD management practices that are not evidence-based and not guideline-supported.
- 8 February 2023
- Published by Springer Nature
- p. 147-153
Evaluation of Male Infertility
- 8 February 2023
- Published by Springer Nature
- p. 155-161
Erectile Dysfunction